brainstorm cell therapeutics (BCLI) Key Developments
Brainstorm Cell Therapeutics Inc. - Shareholder/Analyst Call
Nov 12 13
To update shareholders on the latest positive company developments
BrainStorm Cell Therapeutics to Initiate Study for Multiple Sclerosis at Hadassah Medical Center
Oct 15 13
BrainStorm Cell Therapeutics announced that it will initiate a pre-clinical study for Multiple Sclerosis (MS) at the Hebrew University Hadassah Medical Center's SPF-grade animal laboratory in Jerusalem. The study was approved by the Institutional Animal Care and Use Committee (IACUC) of the Hebrew University. Based on promising pre-clinical data published by the company's Chief Scientist, Prof. Daniel Offen of Tel Aviv University, BrainStorm will conduct further studies using the Experimental Autoimmune Encephalomyelitis (EAE) animal model to evaluate MS as an additional indication for its NurOwn technology. Professor Dimitrios Karussis and Dr. Ibrahim Kassis, who have published extensively on pre-clinical research using the EAE model, will be the Principal Investigators of the study.
BrainStorm Cell Therapeutics Inc. Launches US Activities for Multi-Center ALS Clinical Trial
Oct 1 13
BrainStorm Cell Therapeutics Inc. announced that it has launched its activities in the US in preparation for its Phase IIa multi-center clinical trial, with the initiation of the NurOwn(TM) technology transfer process at the Dana Farber Cancer Institute (DFCI). DFCI's Connell and O'Reilly Cell Manipulation Core Facility will produce NurOwn in its cGMP-compliant clean room facilities for the MGH and UMass Hospital clinical sites. The third clinical site in the trial, Mayo Clinic, will produce NurOwn at its own cleanroom facility. The Cell Manipulation Core Facility (CMCF) at Dana-Farber Cancer Institute (DFCI) is a manufacturing facility that produces safe and effective novel cellular component therapy that meets all regulatory guidelines for clinical use and also facilitates research to be translated from the bench to the bedside. All procedures are performed in environmentally controlled conditions according to current Good Manufacturing Practices (cGMP) for cell and tissue processing.
Brainstorm Cell Therapeutics Inc. - Special Call
Aug 14 13
To update shareholders on recent company developments
Brainstorm Cell Therapeutics Inc. Announces Executive Changes
Aug 1 13
Brainstorm Cell Therapeutics Inc. announced that on July 28, 2013, Alon Natanson, Chief Executive Officer the company informed the company of his resignation from his position with the company effective 90 days after such notice. The company also announced that on August 1, 2013, it appointed Chaim Lebovits, the President of the company, as its principal executive officer. Prior to his appointment as principal executive officer of the company, Mr. Lebovits served as the company’s President since he joined the company in 2007. Mr. Lebovits controls Acc Holdings International, and its subsidiaries ACC Resources and ACC BioTech.